Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review
Open accessThe DOI matches its Crossref record; 165 of the 167 references it cites were found in a registry or an index.
Abstract
As traditional strategies for cancer treatment, some chemotherapy agents, such as doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor effects by inducing immunogenic cell death (ICD) of tumor cells. ICD induces anti-tumor immunity through release of, or exposure to, damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calreticulin, adenosine triphosphate, and heat shock proteins. This leads to activation of tumor-specific immune responses, which can act in combination with the direct killing functions of chemotherapy drugs on cancer cells to further improve their curative effects. In this review, we highlight the molecular mechanisms underlying ICD, including those of several chemotherapeutic drugs in inducing DAMPs exposed during ICD to activate the immune system, as well as discussing the prospects for application and potential role of ICD in cancer immunotherapy, with the aim of providing valuable inspiration for future development of chemoimmunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite this, research suggests that immunogenic cell death (ICD) induced by chemotherapy, targeted therapy, and/or radiotherapy not only leads to cancer cell death but also stimulates anti-tumor immune responses through the release of tumor neoantigens and damage-associated molecular patterns (DAMPs) (Zhai et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Zhai et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Qu, L., Li, K., Liu, K., & Hu, W. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/4959840 · Cited by 2 · cited 1×
“mentioned that the treatment of gemcitabine and oxaliplatin combined with apatinib in gallbladder cancer will significantly increase the level of humoral immune cells, and significantly decrease the levels of sIL-2R, and sICAM-1 to effectively control the progress of the disease by improving the immune function (Qu et…”
BackgroundRetractedImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223 · cited 2×
“DAMPs, such as calreticulin (CRT), adenosine triphosphate (ATP), heat shock protein (HSP), and high mobility group box 1 (HMGB1) (Garg et al., 2010; Krysko et al., 2012; Boada-Romero et al., 2020).”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 4×
“Anthracyclines can trigger exposure to CRT, as well as HSP70 and HSP90 expression, which involves translocation of these markers to the cell surface, and thus induces anti-cancer immune responses and HMGB1 release (Obeid et al., 2007; Fucikova et al., 2011).”
BackgroundInfluentialChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 2×
“The recovery of GSDME expression in tumor cells is helpful to enhance the function of immune cells to inhibit tumor growth (Wang et al., 2017).”
BackgroundImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · cited 2×
“ICD is a form of regulated cell death typically driven by stress (Galluzzi et al., 2017), including cell stress and cell death accompanied by exposure, active secretion, or passive release of large numbers of OPEN ACCESS”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 5×
“In addition, they found that combination treatment of NSCLC with cisplatin and crizotinib induced ICD in vivo (Liu et al., 2019).”
BackgroundInfluentialDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574 · cited 1×
“Similarly, the mechanisms driving ICD have been used to produce DC-based tumor vaccines, and many clinical trials have been completed (Wculek et al., 2020).”
BackgroundMitochondria as multifaceted regulators of cell death
Bock, F. J., & Tait, S. W. G. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0173-8 · Cited by 2,450 · cited 3×
“Among them, mitochondrial outer membrane permeabilization (MOMP) plays a key role in intrinsic apoptosis by activating NF-κB (Bock and Tait, 2020).”
BackgroundNatural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101 · cited 1×
“First, ICD inducers must show superior therapeutic effect when used to treat tumors in mice with normal immune function compared with those with low immune function (Vesely et al., 2011; Garg et al., 2014; Kepp et al., 2014).”
BackgroundDNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834 · cited 1×
“Further, immunostimulatory cytokines, such as type I interferon (IFN), have important roles in cancer treatment (Vanpouille-Box et al., 2017; Cauwels et al., 2018; Sprooten et al., 2019).”
BackgroundCisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751 · cited 2×
“…significant therapeutic effects against testicular germ cell, colorectal, ovarian, bladder, lung, and head and neck cancers (Galanski, 2006; Ghosh, 2019); however, it differs fromOXA in the levels of CRT exposure it induces, and cannot activate PERKdependent eIF2α phosphorylation (Martins…”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Farhood, B., Najafi, M., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27782 · Cited by 1,658 · cited 1×
“As major mediators of tumor cell killing, CTLs have vital roles in cancer treatment (Farhood et al., 2019).”
BackgroundCombining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586 · cited 1×
“Further, treatment approaches combining chemotherapy and immunotherapy are among the most effective cooperative strategies and have made considerable contributions to tackling drug resistant tumor cells (Vanneman and Dranoff, 2012; Smyth et al., 2016).”
BackgroundImmunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · cited 4×
“Gold-standard approaches to prediction of the ICD-inducing capacity of chemotherapeutic agents appear to rely on CRT exposure, ATP secretion, and HMGB1 release by human cancer cells (Galluzzi et al., 2015).”
BackgroundInfluentialCDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · cited 2×
“, 2020); 3) targeted anti-cancer drugs (cetuximab, crizotinib, ceritinib, and ibrutinib) (Sagiv-Barfi et al., 2015; Pozzi et al., 2016; Goel et al., 2017; Liu et al., 2019; Petroni et al., 2020; Petrazzuolo et al., 2021); and 4) various physical therapies (radiotherapy, external phototherapy, and photodynamic therapy,…”
BackgroundAutophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377 · cited 2×
“After the inflammasome is activated, newly-recruited DC precursors undergo maturation in response to ATP, and their ability to recognize and present tumor antigen is enhanced, thereby initiating adaptive anti-cancer immunity (Michaud et al., 2011).”
BackgroundGhiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241 · cited 1×
“A circulating low-dose CPA regimen restored peripheral T cell proliferation and innate killing activities by inhibiting human CD4 CD25regulatory T cells (Ghiringhelli et al., 2007).”
BackgroundLymphocyte-Mediated Cytotoxicity
Russell, J. H., & Ley, T. J. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100201.131730 · Cited by 1,122 · cited 1×
“Activated CTLs mainly kill target cells through granule exocytosis and Fas ligand (FasL)-mediated apoptosis induction, thus achieving tumor clearance (Russell and Ley, 2002).”
BackgroundConsensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119 · cited 1×
“Once the CRT/ ERp57 molecular complex is co-transferred and exposed on the cell surface, it promotes phagocytosis by dendritic cells (DCs) (Krysko et al., 2012; Galluzzi et al., 2020; Fucikova et al., 2021).”
BackgroundA bioorthogonal system reveals antitumour immune function of pyroptosis
Wang, Q., Wang, Y., Ding, J., Wang, C., Zhou, X., Gao, W., Huang, H., Shao, F., & Liu, Z. (2020) · Nature · doi:10.1038/s41586-020-2079-1 · Cited by 1,083
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050 · cited 1×
“Cyclophosphamide (CPA) is a drug used for a wide range of cancer treatments, and has remarkable curative effects on lymphoma and solid tumors, including breast cancer, ovarian cancer, and bone and soft tissue sarcoma (Emadi et al., 2009).”
BackgroundCombination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“Further, treatment approaches combining chemotherapy and immunotherapy are among the most effective cooperative strategies and have made considerable contributions to tackling drug resistant tumor cells (Vanneman and Dranoff, 2012; Smyth et al., 2016).”
BackgroundGardella, S., Andrei, C., Ferrera, D., Lotti, L. V., Torrisi, M. R., Bianchi, M. E., & Rubartelli, A. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf198 · Cited by 926 · cited 1×
“nuclear component of non-histone chromatin binding that is passively released by dead cells (Gardella et al., 2002).”
BackgroundPhagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911 · cited 1×
“These signals must be considered in order to achieve the better anti-tumor response (Feng et al., 2019).”
BackgroundThe clearance of dead cells by efferocytosis
Boada-Romero, E., Martinez, J., Heckmann, B. L., & Green, D. R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0232-1 · Cited by 876 · cited 1×
“DAMPs, such as calreticulin (CRT), adenosine triphosphate (ATP), heat shock protein (HSP), and high mobility group box 1 (HMGB1) (Garg et al., 2010; Krysko et al., 2012; Boada-Romero et al., 2020).”
BackgroundApoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA
Rongvaux, A., Jackson, R., Harman, C. C. D., Li, T., West, A. P., de Zoete, M. R., Wu, Y., Yordy, B., Lakhani, S. A., Kuan, C.-Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.037 · Cited by 847 · cited 3×
“Among them, mitochondrial outer membrane permeabilization (MOMP) plays a key role in intrinsic apoptosis by activating NF-κB (Bock and Tait, 2020).”
BackgroundConsensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832 · cited 3×
“First, ICD inducers must show superior therapeutic effect when used to treat tumors in mice with normal immune function compared with those with low immune function (Vesely et al., 2011; Garg et al., 2014; Kepp et al., 2014).”
BackgroundChao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776 · cited 1×
“In addition, CD47 on tumor cell membrane can inhibit the phagocytosis of DC to tumor cells (Chao et al., 2010).”
BackgroundPatnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743 · cited 5×
“In addition, they found that combination treatment of NSCLC with cisplatin and crizotinib induced ICD in vivo (Liu et al., 2019).”
BackgroundInfluentialKazama, H., Ricci, J.-E., Herndon, J. M., Hoppe, G., Green, D. R., & Ferguson, T. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.013 · Cited by 627 · cited 1×
“Caspase proteases can also inhibit IFN reaction and indirectly inactivate HMGB1 in damps to keep apoptosis immunologically silent, thus affecting the process of apoptosis (Kazama et al., 2008; Rongvaux et al., 2014; Ning et al., 2019).”
BackgroundRadiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Helen Barcellos-Hoff, M., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 624 · cited 1×
“Comparable results were reported in murine glioma cells (KR158), murine lung carcinoma (LLC), murine mammary adenocarcinoma (TSA), and human (Panc-1) and murine (Pan02) pancreatic tumor cell lines (Golden et al., 2014; Zhao X. et al., 2016; Roberts et al., 2018; Sun et al., 2019).”
ResultThe extracellular release of HMGB1 during apoptotic cell death
Bell, C. W., Jiang, W., Reich, C. F., & Pisetsky, D. S. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00616.2005 · Cited by 538 · cited 1×
“In the late stages of apoptosis, when cells are damaged and disrupted, HMGB1 released from nuclei can be detected by enzymelinked immunosorbent assay (Bell et al., 2006).”
BackgroundLoi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536 · cited 2×
“…can increase numbers of tumor infiltrating lymphocytes, which is associated with favorable prognosis in patients with triplenegative breast cancer (Loi et al., 2016); however, there was no significant difference in adaptive immune response between animals treated with DOX liposomes alone and…”
BackgroundMethodAnthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Henriksen, P. A. (2018) · Heart · doi:10.1136/heartjnl-2017-312103 · Cited by 536 · cited 1×
“Compared with traditional anthracycline drugs, anthracycline liposome preparations exhibit significantly reduced cardiotoxicity due to the influence of microvascular penetration (Henriksen, 2018).”
BackgroundVandivier, R. W., Ogden, C. A., Fadok, V. A., Hoffmann, P. R., Brown, K. K., Botto, M., Walport, M. J., Fisher, J. H., Henson, P. M., & Greene, K. E. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3978 · Cited by 516 · cited 1×
“It can form a bridging complex with CD91 molecule on the surface of phagocytes to initiate clearance (Vandivier et al., 2002) Besides, when cells are in a pre-apoptotic stage, CRT is translocated to the cell periphery by immunogenic dead cells, along with ERp57.”
BackgroundProgrammed cell death and the immune system
Nagata, S., & Tanaka, M. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.153 · Cited by 512 · cited 1×
“Apoptotic cells release their contents, including DAMPs, which act as hazard signals that produce immunostimulatory effects, including recruitment and activation of various immune cells, such as neutrophils and macrophages (Nagata and Tanaka, 2017).”
BackgroundZhou, F., Feng, B., Yu, H., Wang, D., Wang, T., Ma, Y., Wang, S., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805888 · Cited by 507 · cited 1×
“reported a type of prodrug vesicle, which integrated an OXA prodrug and a PEGylated photosensitizer, and further improved the curative effect of anticancer immunotherapy by inducing ICD and blocking CD47, to promote antigen presentation by DCs in mouse colorectal tumors, breast tumors, and melanoma cells (Zhou et al.,…”
BackgroundImmunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496 · cited 2×
“DAMPs, such as calreticulin (CRT), adenosine triphosphate (ATP), heat shock protein (HSP), and high mobility group box 1 (HMGB1) (Garg et al., 2010; Krysko et al., 2012; Boada-Romero et al., 2020).”
BackgroundMolecular characteristics of immunogenic cancer cell death
Tesniere, A., Panaretakis, T., Kepp, O., Apetoh, L., Ghiringhelli, F., Zitvogel, L., & Kroemer, G. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402269 · Cited by 494 · cited 1×
“In addition, HSP70 can also induce NK cell activation and promote DC maturation, thus inducing tumor cell death (Tesniere et al., 2008).”
BackgroundCDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464 · cited 1×
“Cyclin-dependent kinases 4 and 6 (CDK4/6) are key molecules involved in cell cycle regulation, which are closely associated with the occurrence and development of malignant tumors (Fassl et al., 2022).”
BackgroundChemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452
Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity
Aaes, T. L., Kaczmarek, A., Delvaeye, T., De Craene, B., De Koker, S., Heyndrickx, L., Delrue, I., Taminau, J., Wiernicki, B., De Groote, P., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.037 · Cited by 443 · cited 4×
“Among them, mitochondrial outer membrane permeabilization (MOMP) plays a key role in intrinsic apoptosis by activating NF-κB (Bock and Tait, 2020).”
BackgroundInfluentialDying cells actively regulate adaptive immune responses
Yatim, N., Cullen, S., & Albert, M. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.9 · Cited by 442 · cited 1×
“DAMPs can interact with the immune system, thereby altering immunogenic outcomes, as well as regulating the types of cell death that occur (Yatim et al., 2017).”
BackgroundYu, Z., Guo, J., Hu, M., Gao, Y., & Huang, L. (2020) · ACS Nano · doi:10.1021/acsnano.0c00708 · Cited by 433 · cited 1×
“reported that a combination of low dose DOX and icariin acted synergistically to induce ICD, thereby improving the curative effects of ICD in hepatocellular carcinoma (Yu et al., 2020).”
BackgroundMartins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414 · cited 1×
“Cisdiamminedichloroplatinum (better known as cisplatin or CDDP) is a platinum drug that is widely used for treatment of malignant tumors and exhibits significant therapeutic effects against testicular germ cell, colorectal, ovarian, bladder, lung, and head and neck cancers (Galanski, 2006; Ghosh, 2019); however, it di…”
BackgroundFucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 400 · cited 1×
“Once the CRT/ ERp57 molecular complex is co-transferred and exposed on the cell surface, it promotes phagocytosis by dendritic cells (DCs) (Krysko et al., 2012; Galluzzi et al., 2020; Fucikova et al., 2021).”
BackgroundHuman Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392 · cited 8×
“ICD-related cellular stressors exploited for clinic treatment include, but are not limited to: 1) therapeutic oncolytic viruses (Brown et al., 2017; Fend et al., 2017); 2) conventional chemotherapy drugs, such as anthracyclines [doxorubicin (DOX), mitoxantrone (MTX) etc.] (Obeid et al., 2007; Fucikova et al., 2011), a…”
BackgroundInfluentialContext-dependent roles of complement in cancer
Roumenina, L. T., Daugan, M. V., Petitprez, F., Sautès-Fridman, C., & Fridman, W. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0210-0 · Cited by 389 · cited 1×
“, 2019), and additional chemoimmunotherapy regimens with potential anti-cancer effects have been discovered based on this mechanism (Galluzzi et al., 2019; Roumenina et al., 2019).”
BackgroundSpisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388 · cited 2×
“, 2020), proteasome inhibitors [bortezomib (BTZ)] (Spisek et al., 2007; Gulla et al., 2021), and paclitaxel (PTX) (Lau et al.”
BackgroundSnyder, A. G., Hubbard, N. W., Messmer, M. N., Kofman, S. B., Hagan, C. E., Orozco, S. L., Chiang, K., Daniels, B. P., Baker, D., & Oberst, A. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw2004 · Cited by 374 · cited 3×
“Among them, mitochondrial outer membrane permeabilization (MOMP) plays a key role in intrinsic apoptosis by activating NF-κB (Bock and Tait, 2020).”
BackgroundSchiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362 · cited 2×
“, 2011), and DNA damaging agents [cyclophosphamide (CPA), platinum derivatives, but excluding cisplatin] (Schiavoni et al., 2011; Kopecka et al., 2018; Limagne et al., 2019; Wang et al., 2019; Yamazaki et al., 2020), proteasome inhibitors [bortezomib (BTZ)] (Spisek et al.”
BackgroundColorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches
McQuade, R. M., Stojanovska, V., Bornstein, J. C., & Nurgali, K. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170111152436 · Cited by 350
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347 · cited 2×
“Further, numerous studies have confirmed that some chemotherapeutic agents can induce ICD to enhance tumor cell immunogenicity (Inoue and Tani, 2014; Vanmeerbeek et al., 2020).”
BackgroundPivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333 · cited 1×
“γδ T lymphocytes, which produce interleukin-17 (IL-17) are also associated with the subsequent adaptive immune response (Mattarollo et al., 2011; Kepp et al., 2014).”
BackgroundZhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153550 · Cited by 330 · cited 1×
“As the signal of “do not eat me”, when CD47 is blocked, the phagocytosis of macrophages is induced (Zhang et al., 2016).”
BackgroundTreatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Sartore-Bianchi, A. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 329 · cited 1×
“, 2021) (Table 3), such as cetuximab, which is used for treatment of patients with metastatic colorectal cancer (mCRC) (Modest et al., 2019).”
BackgroundSeicean, S., Seicean, A., Plana, J. C., Budd, G. T., & Marwick, T. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.067 · Cited by 326 · cited 1×
“In addition, because DOXinduced cardiotoxicity is related to oxidative stress, according to this mechanism, several cardioprotective drugs including dexrazoxane, statins and coenzyme Q10 have been proved to be effective in the mouse model (Trajković et al., 2007; Seicean et al., 2012; Chen et al., 2017).”
BackgroundImmunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320 · cited 1×
“In addition, determining dosage and treatment plans that mediate maximal immunostimulation is an ongoing major challenge (Zhao X.Y. et al., 2016; Wu and Waxman, 2018).”
BackgroundApoptotic Caspases Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS, and IRF3
Ning, X., Wang, Y., Jing, M., Sha, M., Lv, M., Gao, P., Zhang, R., Huang, X., Feng, J.-M., & Jiang, Z. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.013 · Cited by 317 · cited 1×
“Caspase proteases can also inhibit IFN reaction and indirectly inactivate HMGB1 in damps to keep apoptosis immunologically silent, thus affecting the process of apoptosis (Kazama et al., 2008; Rongvaux et al., 2014; Ning et al., 2019).”
BackgroundCrizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302 · cited 2×
“, 2020); 3) targeted anti-cancer drugs (cetuximab, crizotinib, ceritinib, and ibrutinib) (Sagiv-Barfi et al., 2015; Pozzi et al., 2016; Goel et al., 2017; Liu et al., 2019; Petroni et al., 2020; Petrazzuolo et al., 2021); and 4) various physical therapies (radiotherapy, external phototherapy, and photodynamic therapy,…”
BackgroundThe EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292 · cited 2×
“, 2020); 3) targeted anti-cancer drugs (cetuximab, crizotinib, ceritinib, and ibrutinib) (Sagiv-Barfi et al., 2015; Pozzi et al., 2016; Goel et al., 2017; Liu et al., 2019; Petroni et al., 2020; Petrazzuolo et al., 2021); and 4) various physical therapies (radiotherapy, external phototherapy, and photodynamic therapy,…”
BackgroundTaxol®: The First Microtubule Stabilizing Agent
Yang, C.-P., & Horwitz, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081733 · Cited by 284 · cited 1×
“Paclitaxel (PTX) is an important and effective anti-tumor drug, which can quickly bind and stabilize microtubules (Yang and Horwitz, 2017).”
BackgroundBarr, P. M., Owen, C., Robak, T., Tedeschi, A., Bairey, O., Burger, J. A., Hillmen, P., Coutre, S. E., Dearden, C., Grosicki, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006434 · Cited by 282 · cited 1×
“Ibrutinib is another targeted drug with significant anti-tumor effects against chronic lymphocytic leukemia, which has shown sustained benefits for patients in clinical studies (Barr et al., 2022).”
BackgroundChemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278 · cited 1×
“Another sign of ICD is secretion of ATP by dead cancer cells, which is considered to be a ‘find me’ signal (Martins et al., 2009).”
BackgroundTrial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276 · cited 2×
“Over the decades, two standards have been established to identify genuine ICD inducers in vivo (Garg et al., 2017a).”
BackgroundGarg, A. D., Vandenberk, L., Koks, C., Verschuere, T., Boon, L., Van Gool, S. W., & Agostinis, P. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0105 · Cited by 270 · cited 1×
“Second, in vitro, cancer cells succumbing to genuine ICD inducers can vaccinate syngeneic immunocompetent hosts and fight subsequent attack with living cancer cells of the same type (Garg et al., 2016); however, it is not possible to discriminate genuine ICD inducers and chemotherapeutic drugs with immunostimulatory e…”
BackgroundMitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency
Giampazolias, E., Zunino, B., Dhayade, S., Bock, F., Cloix, C., Cao, K., Roca, A., Lopez, J., Ichim, G., Proïcs, E., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3596 · Cited by 258 · cited 2×
“Among them, mitochondrial outer membrane permeabilization (MOMP) plays a key role in intrinsic apoptosis by activating NF-κB (Bock and Tait, 2020).”
BackgroundZhao, X., Yang, K., Zhao, R., Ji, T., Wang, X., Yang, X., Zhang, Y., Cheng, K., Liu, S., Hao, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.032 · Cited by 256
Song, Q., Yin, Y., Shang, L., Wu, T., Zhang, D., Kong, M., Zhao, Y., He, Y., Tan, S., Guo, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03186 · Cited by 254 · cited 1×
“developed a nanogel encapsulating PTX to deliver interleukin −2 (IL-2), which significantly induced CRT exposure and enhanced anti-tumor activity (Song et al., 2017).”
MethodSelf-citationHost tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253 · cited 1×
“Complex immune components in the tumor microenvironment influence immunomodulatory effects on tumors, and may interfere with the therapeutic effects of chemotherapy drugs (Salmon et al., 2019), and additional chemoimmunotherapy regimens with potential anti-cancer effects have been discovered based on this mechanism (G…”
BackgroundcGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
Wang, Z., Chen, J., Hu, J., Zhang, H., Xu, F., He, W., Wang, X., Li, M., Lu, W., Zeng, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127471 · Cited by 253 · cited 1×
“, 2011), and DNA damaging agents [cyclophosphamide (CPA), platinum derivatives, but excluding cisplatin] (Schiavoni et al., 2011; Kopecka et al., 2018; Limagne et al., 2019; Wang et al., 2019; Yamazaki et al., 2020), proteasome inhibitors [bortezomib (BTZ)] (Spisek et al.”
BackgroundPeptide–Drug Conjugates with Different Linkers for Cancer Therapy
Alas, M., Saghaeidehkordi, A., & Kaur, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01530 · Cited by 246 · cited 1×
“In addition to antibody-drug conjugate, the peptide-drug conjugates can improve efficacy and reduce side effects for cancer treatment in cell and animal studies (Alas et al., 2021).”
BackgroundeIF2α phosphorylation is pathognomonic for immunogenic cell death
Bezu, L., Sauvat, A., Humeau, J., Gomes-da-Silva, L. C., Iribarren, K., Forveille, S., Garcia, P., Zhao, L., Liu, P., Zitvogel, L., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0044-9 · Cited by 241 · cited 2×
“MTX, a broad-spectrum anti-tumor anthracycline, has also been shown to induce ICD in melanoma, prostate cancer, osteosarcoma, and mouse colon cancer cells through an eIF2α phosphorylationdependent mechanism, leading to anti-cancer immune responses (Bezu et al., 2018; Giglio et al., 2018; Qin et al., 2019; Li et al., 2…”
BackgroundWNT Signaling in Cancer Immunosurveillance
Galluzzi, L., Spranger, S., Fuchs, E., & López-Soto, A. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.08.005 · Cited by 239 · cited 1×
“, 2019), and additional chemoimmunotherapy regimens with potential anti-cancer effects have been discovered based on this mechanism (Galluzzi et al., 2019; Roumenina et al., 2019).”
BackgroundMitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity
Wu, B. B., Leung, K. T., & Poon, E. N.-Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031912 · Cited by 237 · cited 2×
“Although DOX has a wide range of biochemical effects on tumor cells, it indues significant cytotoxicity in many organs, particularly the heart; the underlying mechanism involves mitochondria damage, iron overload, and perturbed Ca homeostasis, which lead to myocardial damage (Wu et al., 2022).”
BackgroundATP and cancer immunosurveillance
Kepp, O., Bezu, L., Yamazaki, T., Di Virgilio, F., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 229 · cited 1×
“Extracellular ATP from cancer cells that undergo ICD mediates immune system chemotaxis by binding to purinergic receptor P2Y2 (P2RY2), and promoting the secretion of interleukin 1 β (IL-1β) and interleukin-18 (IL-18) by activating inflammatory corpuscles (Kepp et al., 2021).”
BackgroundTrial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227 · cited 4×
“Following Vanmeerbeek’s trial watch in 2020 (Vanmeerbeek et al., 2020), many latest clinical trials have evaluated the real efficacy of various ICD-induced drugs.”
BackgroundInfluentialDanger signalling during cancer cell death: origins, plasticity and regulation
Garg, A. D., Martin, S., Golab, J., & Agostinis, P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.48 · Cited by 226 · cited 7×
“ICD-related cellular stressors exploited for clinic treatment include, but are not limited to: 1) therapeutic oncolytic viruses (Brown et al., 2017; Fend et al., 2017); 2) conventional chemotherapy drugs, such as anthracyclines [doxorubicin (DOX), mitoxantrone (MTX) etc.] (Obeid et al., 2007; Fucikova et al., 2011), a…”
BackgroundInfluentialBrown, M. C., Holl, E. K., Boczkowski, D., Dobrikova, E., Mosaheb, M., Chandramohan, V., Bigner, D. D., Gromeier, M., & Nair, S. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4220 · Cited by 224 · cited 1×
“ICD-related cellular stressors exploited for clinic treatment include, but are not limited to: 1) therapeutic oncolytic viruses (Brown et al., 2017; Fend et al., 2017); 2) conventional chemotherapy drugs, such as anthracyclines [doxorubicin (DOX), mitoxantrone (MTX) etc.”
BackgroundRecent Developments in the Field of Anticancer Platinum Complexes
Galanski, M. S. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206777442287 · Cited by 223 · cited 2×
“…tumors and exhibits significant therapeutic effects against testicular germ cell, colorectal, ovarian, bladder, lung, and head and neck cancers (Galanski, 2006; Ghosh, 2019); however, it differs fromOXA in the levels of CRT exposure it induces, and cannot activate PERKdependent eIF2α…”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212 · cited 1×
“Anti-tumor immune responses also extend to numerous targeted drugs (Galluzzi et al., 2015; Petroni et al., 2021) (Table 3), such as cetuximab, which is used for treatment of patients with metastatic colorectal cancer (mCRC) (Modest et al.”
BackgroundZsiros, E., Lynam, S., Attwood, K. M., Wang, C., Chilakapati, S., Gomez, E. C., Liu, S., Akers, S., Lele, S., Frederick, P. J., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5945 · Cited by 210 · cited 1×
“The combination of cyclophosphamide, pabolizumab and bevacizumab showed good clinical benefits (median PFS = 10.0) in the phase 2 clinical trial (Zsiros et al., 2021).”
BackgroundInfluentialPaclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis
Lau, T. S., Chan, L. K. Y., Man, G. C. W., Wong, C. H., Lee, J. H. S., Yim, S. F., Cheung, T. H., McNeish, I. A., & Kwong, J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0616 · Cited by 195 · cited 11×
“ICD-related cellular stressors exploited for clinic treatment include, but are not limited to: 1) therapeutic oncolytic viruses (Brown et al., 2017; Fend et al., 2017); 2) conventional chemotherapy drugs, such as anthracyclines [doxorubicin (DOX), mitoxantrone (MTX) etc.] (Obeid et al., 2007; Fucikova et al., 2011), a…”
BackgroundInfluentialRegulated cell death and adaptive stress responses
Galluzzi, L., Bravo-San Pedro, J. M., Kepp, O., & Kroemer, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2209-y · Cited by 177
Li, Z., Cai, H., Li, Z., Ren, L. F., Ma, X., Zhu, H., Gong, Q., Zhang, H., Gu, Z., & Luo, K. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.08.028 · Cited by 176 · cited 2×
“engineered a selfamplified biomimetic nanosystem, in which epirubicin, glucose oxidase, and hemin are encapsulated within the core of ZIF-8 nanoparticles, which significantly induced ICD to promote DC maturation and CTL infiltration into tumor lesions (Li et al., 2023).”
BackgroundImmunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
van der Voort, A., van Ramshorst, M. S., van Werkhoven, E. D., Mandjes, I. A. M., Kemper, I., Vulink, A. J. E., Oving, I. M., Honkoop, A. H., Tick, L. W., van de Wouw, A. J., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.1371 · Cited by 171
Tissue-protective effects of fullerenol C60(OH)24 and amifostine in irradiated rats
Trajković, S., Dobrić, S., Jaćević, V., Dragojević-Simić, V., Milovanović, Z., & Đorđević, A. (2007) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2007.01.005 · Cited by 168 · cited 1×
“In addition, because DOXinduced cardiotoxicity is related to oxidative stress, according to this mechanism, several cardioprotective drugs including dexrazoxane, statins and coenzyme Q10 have been proved to be effective in the mouse model (Trajković et al., 2007; Seicean et al., 2012; Chen et al., 2017).”
BackgroundChoi, J., Shim, M. K., Yang, S., Hwang, H. S., Cho, H., Kim, J., Yun, W. S., Moon, Y., Kim, J., Yoon, H. Y., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c03416 · Cited by 166 · cited 1×
“…et al., 2016; Goel et al., 2017; Liu et al., 2019; Petroni et al., 2020; Petrazzuolo et al., 2021); and 4) various physical therapies (radiotherapy, external phototherapy, and photodynamic therapy, etc.) (Gomes-da-Silva et al., 2018; Tatsuno et al., 2019; Choi et al., 2021; Vaes et al., 2021).”
BackgroundClinical Pharmacokinetics and Pharmacodynamics of Bortezomib
Tan, C. R. C., Abdul-Majeed, S., Cael, B., & Barta, S. K. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0679-9 · Cited by 163 · cited 1×
“administration, significantly reduced the probability of peripheral neuropathy while maintaining efficacy (Tan et al., 2019).”
BackgroundImmunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163 · cited 2×
“, 2020); 3) targeted anti-cancer drugs (cetuximab, crizotinib, ceritinib, and ibrutinib) (Sagiv-Barfi et al., 2015; Pozzi et al., 2016; Goel et al., 2017; Liu et al., 2019; Petroni et al., 2020; Petrazzuolo et al., 2021); and 4) various physical therapies (radiotherapy, external phototherapy, and photodynamic therapy,…”
BackgroundZhu, H., Shan, Y., Ge, K., Lu, J., Kong, W., & Jia, C. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00552-2 · Cited by 163 · cited 2×
“In experiments where CDDP and OXA were each applied to mouse hepatoma cells, there was no significant difference between CDDP and the control group, demonstrating that ICD was not effectively induced (Zhu et al., 2020).”
BackgroundTumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
Han, C., Liu, Z., Zhang, Y., Shen, A., Dong, C., Zhang, A., Moore, C., Ren, Z., Lu, C., Cao, X., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0641-5 · Cited by 162 · cited 1×
“Besides, antiPD-L1 and emricasan (a caspase inhibitor) combined with radiation can induce anti-tumor effect for more effective immunotherapy (Han et al., 2020).”
BackgroundDeng, C., Zhang, Q., Jia, M., Zhao, J., Sun, X., Gong, T., & Zhang, Z. (2019) · Advanced Science · doi:10.1002/advs.201801868 · Cited by 158 · cited 1×
“invented a liposome, PEG-FA-Lip, to deliver DOX, which can promote DC maturation and secretion of immune stimulating factors, effectively triggering T cell immune responses, and thus improving its therapeutic effect on solid tumors (Deng et al., 2019).”
BackgroundSelf-citationGuo, J., Yu, Z., Sun, D., Zou, Y., Liu, Y., & Huang, L. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01297-0 · Cited by 158 · cited 2×
“developed a nanoparticle preparation containing OXA derivatives and folinic acid to induce ICD and inhibit tumor growth; use of the preparation in combination with nano-preparations containing active metabolites of 5-Fu synergistically increased its curative effect on CRC and hepatocellular carcinoma in mouse models,…”
BackgroundSelf-citationBortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Gulla, A., Morelli, E., Samur, M. K., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., Prabhala, R. H., Talluri, S., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0047 · Cited by 144 · cited 2×
“BTZ triggers ICD in multiple myeloma cells by activating the cGAS/STING pathway and producing type I IFN, which can be significantly enhanced by STING agonists (Gulla et al., 2021).”
BackgroundLimagne, E., Thibaudin, M., Nuttin, L., Spill, A., Derangère, V., Fumet, J.-D., Amellal, N., Peranzoni, E., Cattan, V., & Ghiringhelli, F. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0228 · Cited by 142 · cited 2×
“, 2011), and DNA damaging agents [cyclophosphamide (CPA), platinum derivatives, but excluding cisplatin] (Schiavoni et al., 2011; Kopecka et al., 2018; Limagne et al., 2019; Wang et al., 2019; Yamazaki et al., 2020), proteasome inhibitors [bortezomib (BTZ)] (Spisek et al.”
BackgroundBiomarkers of Radiotherapy-Induced Immunogenic Cell Death
Vaes, R. D. W., Hendriks, L. E. L., Vooijs, M., & Ruysscher, D. D. (2021) · Cells · doi:10.3390/cells10040930 · Cited by 141 · cited 1×
“…et al., 2016; Goel et al., 2017; Liu et al., 2019; Petroni et al., 2020; Petrazzuolo et al., 2021); and 4) various physical therapies (radiotherapy, external phototherapy, and photodynamic therapy, etc.) (Gomes-da-Silva et al., 2018; Tatsuno et al., 2019; Choi et al., 2021; Vaes et al., 2021).”
BackgroundMolecular therapy for acute myeloid leukaemia
Coombs, C. C., Tallman, M. S., & Levine, R. L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.210 · Cited by 132 · cited 1×
“Idarubicin is a 4demethoxyanthracycline analog of daunorubicin, which can be used to treat acute myelogenous leukemia (Coombs et al., 2016).”
BackgroundThe Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
Schaer, D. A., Geeganage, S., Amaladas, N., Lu, Z. H., Rasmussen, E. R., Sonyi, A., Chin, D., Capen, A., Li, Y., Meyer, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0433 · Cited by 132 · cited 1×
“In addition to research on the effects of these two drugs in inducing ICD, there is evidence that carboplatin can induce the release of HMGB1 and CRT in Colon26 and MC38 cells (Schaer et al., 2019).”
Background(2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2165 · Cited by 127 · cited 1×
“ICD-related cellular stressors exploited for clinic treatment include, but are not limited to: 1) therapeutic oncolytic viruses (Brown et al., 2017; Fend et al., 2017); 2) conventional chemotherapy drugs, such as anthracyclines [doxorubicin (DOX), mitoxantrone (MTX) etc.”
BackgroundType I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124 · cited 1×
“Further, immunostimulatory cytokines, such as type I interferon (IFN), have important roles in cancer treatment (Vanpouille-Box et al., 2017; Cauwels et al., 2018; Sprooten et al., 2019).”
BackgroundYamazaki, T., Buqué, A., Ames, T. D., & Galluzzi, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1721810 · Cited by 121 · cited 2×
“, 2011), and DNA damaging agents [cyclophosphamide (CPA), platinum derivatives, but excluding cisplatin] (Schiavoni et al., 2011; Kopecka et al., 2018; Limagne et al., 2019; Wang et al., 2019; Yamazaki et al., 2020), proteasome inhibitors [bortezomib (BTZ)] (Spisek et al.”
BackgroundGarg, A. D., Vandenberk, L., Fang, S., Fasche, T., Van Eygen, S., Maes, J., Van Woensel, M., Koks, C., Vanthillo, N., Graf, N., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.15 · Cited by 120
Sałat, K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00106-1 · Cited by 120 · cited 1×
“(Sałat, 2020).”
Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus
Gomes‐da‐Silva, L. C., Zhao, L., Bezu, L., Zhou, H., Sauvat, A., Liu, P., Durand, S., Leduc, M., Souquere, S., Loos, F., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798354 · Cited by 118
Regulation of Protein Compartmentalization Expands the Diversity of Protein Function
Shaffer, K. L., Sharma, A., Snapp, E. L., & Hegde, R. S. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.09.001 · Cited by 110 · cited 1×
“CRT is a Ca binding protein which mainly localizes to the endoplasmic reticulum (ER), and has various biological functions, including regulating calcium signal, participating in glycoprotein synthesis, and regulating gene expression (Shaffer et al., 2005).”
BackgroundComparing the effects of different cell death programs in tumor progression and immunotherapy
Messmer, M. N., Snyder, A. G., & Oberst, A. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0214-4 · Cited by 110 · cited 1×
“Immunogenic chemotherapeutic drugs that can induce ICD play an anti-tumor role by mediating the release of damps in addition to inducing apoptosis (Messmer et al., 2019).”
BackgroundSawaki, M., Taira, N., Uemura, Y., Saito, T., Baba, S., Kobayashi, K., Kawashima, H., Tsuneizumi, M., Sagawa, N., Bando, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00184 · Cited by 108 · cited 1×
“(Sawaki et al., 2020).”
Dong, X., Yang, A., Bai, Y., Kong, D., & Lv, F. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119659 · Cited by 105 · cited 2×
“…et al. designed a double fluorescence imaging-guided programmed delivery system including DOX and cytosinephosphate-guanine nanoparticles, which produced good antitumor therapeutic effects by regulating the tumor microenvironment and promoting CD4+ and CD8+ T cell infiltration (Dong et al., 2020).”
BackgroundMethodJarauta, V., Jaime‐Sánchez, P., Gonzalo, Ó., de Miguel, D., Ramírez-Labrada, A., Martínez‐Lostao, L., Anel, A., Pardo, J., Marzo, I., & Naval, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.019 · Cited by 97 · cited 1×
“1S, U266, H929) treated with carfilzomib, while immunogenicity was enhanced when carfilzomib was combined with chloroquine (Jarauta et al., 2016).”
BackgroundDoxorubicin nanoformulations on therapy against cancer: An overview from the last 10 years
D'Angelo, N. A., Noronha, M. A., Câmara, M. C. C., Kurnik, I. S., Feng, C., Araújo, V. H. S., Santos, J. H. P. M., Feitosa, V. A., Molino, J. V. D., Rangel‐Yagui, C. D. O., et al. (2021) · Biomaterials Advances · doi:10.1016/j.msec.2021.112623 · Cited by 97
Lee, E. K., Xiong, N., Cheng, S., Barry, W. T., Penson, R. T., Konstantinopoulos, P. A., Hoffman, M. A., Horowitz, N. S., Dizon, D. S., Stover, E. H., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.028 · Cited by 95 · cited 1×
“, combined pegylated liposomal doxorubicin (PLD) and pembrolizumab in 200 patients with ovarian cancer, found that the ORR and median PFS of combination therapy was better than historical therapy of pembrolizumab alone (Lee et al., 2020).”
BackgroundGarrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003477 · Cited by 91
Luo, R., Firat, E., Gaedicke, S., Guffart, E., Watanabe, T., & Niedermann, G. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1344 · Cited by 91 · cited 1×
“Further, there are reports that CDDP can induce CXCL10 expression in melanoma cells, compared with untreated controls (Luo et al., 2019).”
BackgroundLiposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer
Li, S., Hao, Y., Wang, C., Han, Y., Zhu, Y., Feng, L., Miao, L., & Liu, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.013 · Cited by 91 · cited 1×
“In the latest research, liposomal OXA prodrugs loaded with metformin were demonstrated to enhance cancer immunotherapy, the alleviation of tumor hypoxia by metformin helps OXA induce ICD in mouse colorectal tumor cells (Song et al., 2022).”
BackgroundImmune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer
Aranda, F., Bloy, N., Pesquet, J., Petit, B., Chaba, K., Sauvat, A., Kepp, O., Khadra, N., Enot, D., Pfirschke, C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.234 · Cited by 89
Yang, Q., Shi, G., Chen, X., Lin, Y., Cheng, L., Jiang, Q., Yan, X., Jiang, M., Li, Y., Zhang, H., et al. (2020) · Theranostics · doi:10.7150/thno.45391 · Cited by 89 · cited 3×
“…research into mouse breast cancer (4T1), CRC (CT26 and MC38), lung cancer (LL/2), and ovarian cancer (ID8 and ID8F3) cells, as well as human CRC cells (HCT116), where it causes the exposure of CRT and ERp57 in tumor cells, accompanied by ATP and HMGB1 release (Lau et al., 2020; Yang et al., 2020).”
BackgroundSelf-citationExtracorporeal photochemotherapy induces bona fide immunogenic cell death
Tatsuno, K., Yamazaki, T., Hanlon, D., Han, P., Robinson, E., Sobolev, O., Yurter, A., Rivera-Molina, F., Arshad, N., Edelson, R. L., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1819-3 · Cited by 88
Sagiv-Barfi, I., Kohrt, H. E., Burckhardt, L., Czerwinski, D. K., & Levy, R. (2015) · Blood · doi:10.1182/blood-2014-08-593137 · Cited by 83
Sun, F., Cui, L., Li, T., Chen, S., Jun-mei, S., & Li, D. (2019) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2019.1655050 · Cited by 83 · cited 2×
“reported that no ICD induction was found after treatment of LLC cells with CDDP (20 μM) for 24 h (Sun et al., 2019); however, in some specific cases, CDDP combined with ischemia and reperfusion injury can lead to ICD in murine LLC cells (Zhang et al.”
BackgroundResultCombès, E., Andrade, A. F., Tosi, D., Michaud, H., Coquel, F., Garambois, V., Désigaud, D., Jarlier, M., Coquelle, A., Pasero, P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2807 · Cited by 78
Cameron, D., Morden, J. P., Canney, P. A., Velikova, G., Coleman, R. E., Bartlett, J. M. S., Agrawal, R. K., Banerji, J., Bertelli, G., Bloomfield, D. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30404-7 · Cited by 72 · cited 1×
“Epirubicin, a type of anthracycline, interferes with DNA and RNA synthesis, and can be combined with other chemotherapeutic drugs to treat various malignant tumors, including postoperative lung cancer and breast cancer (Cameron et al., 2017; Annic et al., 2022; Schneeweiss et al., 2022).”
BackgroundCamilio, K. A., Wang, M., Mauseth, B., Waagene, S., Kvalheim, G., Rekdal, Ø., Sveinbjørnsson, B., & Mælandsmo, G. M. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1092-x · Cited by 71 · cited 1×
“studied the potential of combined treatment of triple-negative breast cancer using the oncolytic peptide, LTX-315, together with DOX, and found that these two reagents can trigger anti-cancer immune responses, thus increasing T cell infiltration and limiting tumor growth (Camilio et al., 2019).”
BackgroundMitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression
Li, C., Sun, H., Wei, W., Liu, Q., Wang, Y., Zhang, Y., Lian, F., Liu, F., Li, C., Ying, K., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00544-2 · Cited by 69 · cited 1×
“MTX, a broad-spectrum anti-tumor anthracycline, has also been shown to induce ICD in melanoma, prostate cancer, osteosarcoma, and mouse colon cancer cells through an eIF2α phosphorylationdependent mechanism, leading to anti-cancer immune responses (Bezu et al., 2018; Giglio et al., 2018; Qin et al., 2019; Li et al., 2…”
BackgroundNanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity
Mastria, E. M., Cai, L. Y., Kan, M. J., Li, X., Schaal, J. L., Fiering, S., Gunn, M. D., Dewhirst, M. W., Nair, S. K., & Chilkoti, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.021 · Cited by 65 · cited 1×
“proved that chimeric polypeptide DOX (a nanoparticle DOX preparation) significantly enhanced anti-cancer immunity by stimulating CD8 T cells and limiting tumor growth, metastasis, and spread (Mastria et al., 2018).”
BackgroundGiglio, P., Gagliardi, M., Tumino, N., Antunes, F., Smaili, S. S., Cotella, D., Santoro, C., Bernardini, R., Mattei, M., Piacentini, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466765 · Cited by 63 · cited 1×
“MTX, a broad-spectrum anti-tumor anthracycline, has also been shown to induce ICD in melanoma, prostate cancer, osteosarcoma, and mouse colon cancer cells through an eIF2α phosphorylationdependent mechanism, leading to anti-cancer immune responses (Bezu et al., 2018; Giglio et al., 2018; Qin et al., 2019; Li et al., 2…”
BackgroundAutophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
Wang, Y., Xie, W., Humeau, J., Chen, G., Liu, P., Pol, J., Zhang, Z., Kepp, O., & Kroemer, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000462 · Cited by 63
Self-citationBacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
Groza, D., Gehrig, S., Kudela, P., Holcmann, M., Pirker, C., Dinhof, C., Schueffl, H. H., Sramko, M., Hoebart, J., Alioglu, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424676 · Cited by 61 · cited 1×
“, empty envelopes of Gram-negative bacteria) in OXA chemotherapy, and combined them with OXA to trigger antitumor T cell responses against CT26 murine colon cancer cells and establish long-term immune memory (Groza et al., 2018).”
BackgroundProgress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
Liu, J., Zhao, R., Jiang, X., Li, Z., & Zhang, B. (2021) · Biomolecules · doi:10.3390/biom12010051 · Cited by 61 · cited 11×
“The immunogenicity of a cetuximab-treated mouse CRC cell line (CT26) expressing human EGFR (hEGFR-CT26) increased and the tumor cells induced an effective anti-tumor response (Pozzi et al., 2016).”
BackgroundInfluentialProtective effect of Co‐enzyme Q10 On doxorubicin‐induced cardiomyopathy of rat hearts
Chen, P., Hou, C., Shibu, M. A., Day, C. H., Pai, P., Liu, Z., Lin, T., Viswanadha, V. P., Kuo, C., & Huang, C. (2016) · Environmental Toxicology · doi:10.1002/tox.22270 · Cited by 60 · cited 2×
“In addition, because DOXinduced cardiotoxicity is related to oxidative stress, according to this mechanism, several cardioprotective drugs including dexrazoxane, statins and coenzyme Q10 have been proved to be effective in the mouse model (Trajković et al., 2007; Seicean et al., 2012; Chen et al., 2017).”
BackgroundCauwels, A., Van Lint, S., Garcin, G., Bultinck, J., Paul, F., Gerlo, S., Van der Heyden, J., Bordat, Y., Catteeuw, D., De Cauwer, L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1398876 · Cited by 60 · cited 1×
“Further, immunostimulatory cytokines, such as type I interferon (IFN), have important roles in cancer treatment (Vanpouille-Box et al., 2017; Cauwels et al., 2018; Sprooten et al., 2019).”
BackgroundWu, J., & Waxman, D. J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.033 · Cited by 59 · cited 1×
“In addition, metronomic CPA treatment for subcutaneous growth of GL261 GBM tumors activates strong innate anti-tumor immunity in mice, thus effectively inducing immune-based tumor regression (Wu and Waxman, 2014).”
BackgroundDesign principles of drug combinations for chemotherapy
Wu, D., Pusuluri, A., Vogus, D. R., Krishnan, V., Shields, C. W., Kim, J., Razmi, A. N., & Mitragotri, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.018 · Cited by 54 · cited 1×
“, 2016); however, there was no significant difference in adaptive immune response between animals treated with DOX liposomes alone and untreated control groups in experiments using the highly invasive 4T1 mouse breast cancer tumor model (Wu et al., 2020).”
MethodLiposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response
Gilabert‐Oriol, R., Ryan, G. M., Leung, A. W. Y., Firmino, N. S., Bennewith, K. L., & Bally, M. B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102922 · Cited by 53 · cited 5×
“In addition, they found that combination treatment of NSCLC with cisplatin and crizotinib induced ICD in vivo (Liu et al., 2019).”
BackgroundInfluentialWang, R., Xu, X., Li, D., Zhang, W., Shi, X., Xu, H., Hong, J., Yao, S., Liu, J., Wei, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121737 · Cited by 49 · cited 1×
“In research related to nano-drugs, smart pH-responsive polyhydrazine/BTZ nanoparticles were more effective in inducing ICD of 4T1 cells and inhibiting lung metastasis than BTZ alone (Wang et al., 2022).”
BackgroundGarrido, G., Lorenzano, P., Sánchez, B., Beausoleil, I., Alonso, D. F., Pérez, R., & Fernandez, L. E. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0313-4 · Cited by 48 · cited 1×
“Dying D122 cells treated with 7A7 also made a major contribution to stimulate DC maturation, and increased the infiltration of CD4+T cells and CD8+T cells (Garrido et al., 2007).”
BackgroundRoberts, N. B., Alqazzaz, A., Hwang, J. R., Qi, X., Keegan, A. D., Kim, A. J., Winkles, J. A., & Woodworth, G. F. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2979-1 · Cited by 46 · cited 1×
“Comparable results were reported in murine glioma cells (KR158), murine lung carcinoma (LLC), murine mammary adenocarcinoma (TSA), and human (Panc-1) and murine (Pan02) pancreatic tumor cell lines (Golden et al., 2014; Zhao X. et al., 2016; Roberts et al., 2018; Sun et al., 2019).”
ResultPoupon-Bejuit, L., Kerckhove, N., Vein, J., Lamoine, S., Authier, N., Busserolles, J., & Balayssac, D. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1056777 · Cited by 40 · cited 1×
“According to the current results of clinical trials, nodrug can be a gold standard to prevent the neurotoxicity of OXA and the preventive measure depends on the dose adjustment of the OXA (Poupon et al., 2015).”
BackgroundDosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
Nikanjam, M., Patel, H., & Kurzrock, R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338997 · Cited by 40
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma
Kopecka, J., Salaroglio, I. C., Righi, L., Libener, R., Orecchia, S., Grosso, F., Milosevic, V., Ananthanarayanan, P., Ricci, L., Capelletto, E., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.022 · Cited by 39 · cited 1×
“, 2011), and DNA damaging agents [cyclophosphamide (CPA), platinum derivatives, but excluding cisplatin] (Schiavoni et al., 2011; Kopecka et al., 2018; Limagne et al., 2019; Wang et al., 2019; Yamazaki et al., 2020), proteasome inhibitors [bortezomib (BTZ)] (Spisek et al.”
BackgroundSchneeweiß, A., Michel, L. L., Möbus, V. J., Tesch, H., Klare, P., Hahnen, E., Denkert, C., Kast, K., Pohl‐Rescigno, E., Hanusch, C. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.011 · Cited by 39 · cited 1×
“Epirubicin, a type of anthracycline, interferes with DNA and RNA synthesis, and can be combined with other chemotherapeutic drugs to treat various malignant tumors, including postoperative lung cancer and breast cancer (Cameron et al., 2017; Annic et al., 2022; Schneeweiss et al., 2022).”
BackgroundIntegrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy
Monk, B. J., Facciabene, A., Brady, W. E., Aghajanian, C. A., Fracasso, P. M., Walker, J. L., Lankes, H. A., Manjarrez, K. L., Danet-Desnoyers, G.-A., Bell‐McGuinn, K. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1453 · Cited by 37 · cited 1×
“Monk et al. reported that combining a Toll-like receptor 8 (TLR8) agonist with pegylated liposomal DOX significantly inhibited the growth of ovarian carcinoma in mice with a humanized immune system (Monk et al., 2017).”
BackgroundMahtani, R. L., Parisi, M., Glück, S., Ni, Q., Park, S., Pelletier, C. L., Faria, C., & Braiteh, F. (2018) · Cancer Management and Research · doi:10.2147/cmar.s150960 · Cited by 36 · cited 1×
“Nab-paclitaxel, a nano-preparation of paclitaxel, reduces the frequency of neuropathy, anemia, pain and diarrhea in patients with metastatic breast cancer (Mahtani et al., 2018).”
BackgroundGao, J., Deng, F., & Jia, W.-D. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e23 · Cited by 36 · cited 1×
“found that a combination treatment with DOX and the small molecule IDO1 inhibitor, NLG919, significantly inhibited the growth of 4T1 murine breast cancer cells compared with single treatments, which only slightly limited the tumor growth rate (Gao et al., 2019).”
BackgroundPetrazzuolo, A., Perez-Lanzon, M., Martins, I., Liu, P., Kepp, O., Minard-Colin, V., Maiuri, M. C., & Kroemer, G. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03997-x · Cited by 36 · cited 2×
“, 2020); 3) targeted anti-cancer drugs (cetuximab, crizotinib, ceritinib, and ibrutinib) (Sagiv-Barfi et al., 2015; Pozzi et al., 2016; Goel et al., 2017; Liu et al., 2019; Petroni et al., 2020; Petrazzuolo et al., 2021); and 4) various physical therapies (radiotherapy, external phototherapy, and photodynamic therapy,…”
BackgroundFerrer‐Font, L., Arias‐Ramos, N., Lope‐Piedrafita, S., Julià‐Sapé, M., Pumarola, M. B., Arús, C., & Candiota, A. P. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3748 · Cited by 35 · cited 1×
“Similarly, metronomic CPA treatment improves the survival rate of model mice with subcutaneous GL261 GBM tumors by influencing immune function (Ferrer-Font et al., 2017).”
BackgroundZhang, Y., Mei, Q., Liu, Y., Li, X., Brock, M. V., Chen, M., Dong, L., Shi, L., Wang, Y., Guo, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1323619 · Cited by 31
Self-citationZhao, X., Zhao, X.-S., Wang, Y.-T., Chen, Y., Xu, L., Zhang, X., Han, W., Chen, H., Wang, Y., Yan, C., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1250992 · Cited by 29
Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML
Aurelius, J., Möllgård, L., Kiffin, R., Sander, F. E., Nilsson, S., Thorén, F. B., Hellstrand, K., & Martner, A. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1599110 · Cited by 29 · cited 1×
“Further, daunorubicin was reported to trigger strong upregulation of CRT on the surface of primary human CD34 acute myeloid leukemia (AML) cells, inducing ICD (Aurelius et al., 2019).”
BackgroundYamaguchi, K., Minashi, K., Sakai, D., Nishina, T., Omuro, Y., Tsuda, M., Iwagami, S., Kawakami, H., Esaki, T., Sugimoto, N., et al. (2022) · Cancer Science · doi:10.1111/cas.15462 · Cited by 28 · cited 1×
“However, there is no difference in two kinds of platinum agents (Yamaguchi et al., 2022).”
BackgroundImmunogenic cell death in a combined synergic gene- and immune-therapy against cancer
Nayagom, B., Amara, I., Habiballah, M., Amrouche, F., Beaune, P. H., & de Waziers, I. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1667743 · Cited by 27 · cited 1×
“, reported sensitization of tumor cells to anticancer agents by transfer of suicide genes; mesenchymal stem cells expressing suicide genes metabolize CPA into toxic metabolites, further induce ICD and DAMPs release, and significantly enhance tumor immunogenicity (Nayagom et al., 2019).”
BackgroundWildiers, H. P. M. W., Meyskens, T., Marreaud, S. I., Lago, L. D., Vuylsteke, P., Curigliano, G., Waters, S. H., Brouwers, B. A. H., Meulemans, B., Sousa, B., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.05.004 · Cited by 25
Çaçan, E., Spring, A. M., Kumari, A., Greer, S. F., & Garnett‐Benson, C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226238 · Cited by 24
Xu, Q., Chen, C., An, L., & Xie, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.17678 · Cited by 24 · cited 1×
“There is evidence that the molecular activity of ICD induced by anticancer drugs may be related to activation of an ER stress-mediated CRT expression pathway, thus inducing immunogenic apoptosis of cancer cells (Xu et al., 2017).”
BackgroundChemotherapy and immunotherapy: A close interplay to fight cancer?
Hanoteau, A., & Moser, M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1190061 · Cited by 23 · cited 1×
“…cancer Enhance antigen presentation and stimulate cytotoxic T cells Increase tumor immunogenicity and induce tumor regression Goel et al. (2017) Frontiers in Pharmacology frontiersin.org09 based on empirical evidence (Hanoteau and Moser, 2016; Nikanjam et al., 2017; Zhang et al., 2017).”
BackgroundHaney, S. L., Varney, M. L., Williams, J. T., Smith, L. M., Talmon, G. A., & Holstein, S. A. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00261-6 · Cited by 19 · cited 1×
“Recent research demonstrated that cell surface translocation of CRT was enhanced by a combination of BTZ and geranylgeranyl diphosphate synthase inhibitor, leading to enhanced immunogenicity (Haney et al., 2022).”
BackgroundZhang, S., Li, Y., Liu, S., Ma, P., Guo, M., Zhou, E., Duan, L., Fan, J., Liao, T., Tan, Q., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05176-y · Cited by 18 · cited 1×
“, 2019); however, in some specific cases, CDDP combined with ischemia and reperfusion injury can lead to ICD in murine LLC cells (Zhang et al., 2022).”
BackgroundQin, J., Kunda, N. M., Qiao, G., Tulla, K. A., Prabhakar, B. S., & Maker, A. V. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.07.068 · Cited by 17 · cited 2×
“MTX, a broad-spectrum anti-tumor anthracycline, has also been shown to induce ICD in melanoma, prostate cancer, osteosarcoma, and mouse colon cancer cells through an eIF2α phosphorylationdependent mechanism, leading to anti-cancer immune responses (Bezu et al., 2018; Giglio et al., 2018; Qin et al., 2019; Li et al., 2…”
BackgroundKanekiyo, S., Hazama, S., Takenouchi, H., Nakajima, M., Shindo, Y., Matsui, H., Tokumitsu, Y., Tomochika, S., Tsunedomi, R., Tokuhisa, Y., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6288 · Cited by 16 · cited 12×
“The immunogenicity of a cetuximab-treated mouse CRC cell line (CT26) expressing human EGFR (hEGFR-CT26) increased and the tumor cells induced an effective anti-tumor response (Pozzi et al., 2016).”
MethodInfluentialLi, J., Ek, F., Olsson, R., Belting, M., & Bengzon, J. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01422-8 · Cited by 14 · cited 1×
“During a search for effective drugs against CD105 glioblastoma (GBM), Li et al. determined that idarubicin has strong toxic effects against CD105 GBM cells (Li et al., 2022).”
BackgroundBorlenghi, E., Cattaneo, C. M., Bertoli, D., Cerqui, E., Archetti, S., Passi, A., Oberti, M., Zollner, T., Giupponi, C., Pagani, C., et al. (2022) · Cancers · doi:10.3390/cancers14194716 · Cited by 13 · cited 1×
“According to data from a retrospective study, high-dose cytarabine plus idarubicin consolidation therapy had strong antileukemia effects in patients with fms-like tyrosine kinase (FLT3) wild-type and mutant AML that carried an nucleophosmin 1 (NPM1) mutation (Borlenghi et al., 2022).”
MethodAnnic, J., Babey, H., Corre, R., Descourt, R., Quéré, G., Renaud, E., Lambert, M., Noach, P., Dhamelincourt, E., Nguyen, J., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5143 · Cited by 8 · cited 1×
“Epirubicin, a type of anthracycline, interferes with DNA and RNA synthesis, and can be combined with other chemotherapeutic drugs to treat various malignant tumors, including postoperative lung cancer and breast cancer (Cameron et al., 2017; Annic et al., 2022; Schneeweiss et al., 2022).”
Background
Cited by
Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00515-6 · Cited by 690
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Peng, Y., Liang, S., Meng, Q., Liu, D., Ma, K., Zhou, M., Yun, K., Rao, L., & Wang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202313188 · Cited by 100
Hänggi, K., Li, J., Gangadharan, A., Liu, X., Celias, D. P., Osunmakinde, O., Keske, A., Davis, J., Ahmad, F. F., Giron, A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.014 · Cited by 93
Elzoghby, A. O., Samir, O., Emam, H. E., Soliman, A., Abdelgalil, R. M., Elmorshedy, Y. M., Elkhodairy, K. A., & Nasr, M. L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.022 · Cited by 58
“The proteasome inhibitor bortezomib (BTZ) 41 , tyrosine kinase inhibitor crizotinib 42,43 , multi-kinase inhibitor, regorafenib 44,45 , and pyruvate kinase M2 (PKM2) inhibitor shikonin (SHK) 46,47 , are among ICD inducers 48,49 .”
BackgroundRole of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy
Song, C. W., Kim, H., Kim, M.-S., Park, H. J., Paek, S.-H., Terezakis, S. A., & Cho, L. C. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.255 · Cited by 65
“2) [34,35,42,72,75].”
Metadata
- Authors
- Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z.
- Affiliations
- Sheng Jing Hospital (CN)
- Corresponding author
- Zhang, Zhenyong
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-04-21
- Volume
- 14
- Pages
- 1152934-1152934
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10160433
- OpenAlex
- W4366690216
- Cited by
- 131
- References
- 167
- Citations by year
- 2026: 36 · 2025: 51 · 2024: 38 · 2023: 6
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- immunogenic cell death, targeted therapy, HMGB1, calreticulin, ATP, heat shock proteins, tumor immunology, chemoimmunotherapy, doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, paclitaxel, antitumor immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.